Expression Profiles of Circulating MicroRNAs in XELOX-Chemotherapy-Induced Peripheral Neuropathy in Patients with Advanced Gastric Cancer

Ju, Yeongdon; Seol, Young Mi; Kim, Jungho; Jin, Huang; Choi, Go-Eun; Jang, Aelee

doi:10.3390/ijms23116041

Cited by 3 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…98 Additionally, blood-based biomarkers as indicators of CIPN severity would be beneficial both diagnostically and for the assessment of neuroprotectants. In both preclinical and clinical settings, a number of studies have suggested that neurotrophic nerve growth factor (NGF) 99,100 and microRNAs 101,102 may be valid markers. Of interest, preclinical studies indicate mitochondrial DNA (mtDNA) may be a useful early biomarker, 103 whilst clinical studies have indicated that brainderived neurotrophic factor (BDNF), [104][105][106] and various other agents such as circulating sphingosine-1-phosphate (S1P) might be candidates.…”

Section: Pathological Assessments With Preclinical and Clinical Relev...mentioning

confidence: 99%

Targeting translation: A review of preclinical animal models in the development of treatments for chemotherapy‐induced peripheral neuropathy

White

Abdulla

Park

et al. 2023

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Background and Aims The expanding use of chemotherapy in curative cancer treatment has simultaneously resulted in a substantial and growing cohort of cancer survivors with prolonged disability from chemotherapy‐induced peripheral neuropathy (CIPN). CIPN is associated with several commonly prescribed chemotherapeutics, including taxanes, platinum‐based drugs, vinca alkaloids, bortezomib and thalidomide. These distinct classes of chemotherapeutics, with their varied neurotoxic mechanisms, often cause patients to suffer from a broad profile of neuropathic symptoms including chronic numbness, paraesthesia, loss of proprioception or vibration sensation and neuropathic pain. Decades of investigation by numerous research groups have provided substantial insights describing this disease. Despite these advances, there is currently no effective curative or preventative treatment option for CIPN and only the dual serotonin–norepinephrine reuptake inhibitor Duloxetine is recommended by clinical guidelines for the symptomatic treatment of painful CIPN. Methods In this review, we examine current preclinical models, with our analysis focused on translational relevance and value. Results Animal models have been pivotal in achieving a better understanding of the pathogenesis of CIPN. However, it has been challenging for researchers to develop appropriate preclinical models that are effective vehicles for the discovery of translatable treatment options. Interpretation Further development of preclinical models targeting translational relevance will promote value for preclinical outcomes in CIPN studies.

show abstract